Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient

References

• SimonneauGGalièNRubinLJClinical classification of pulmonary hypertensionJ Am Coll Cardiol200443Suppl S5S12S15194173
   PubMedGoogle Scholar
• FarberHWLoscalzoJMechanisms of disease: pulmonary hypertensionNew Engl J Med20043511655166515483284
   PubMed Web of Science ®Google Scholar
• BarstRMcGoonMTorbickiADiagnosis and differential assessment of pulmonary arterial hypertensionJ Am Coll Cardiol200443SupplS4047
   Google Scholar
• SunXGHansenJEOudizRJExercise pathophysiology in patients with primary pulmonary hypertensionCirculation200110442943511468205
   PubMed Web of Science ®Google Scholar
• McGoonMGuttermanDSteenVScreening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP Evidence-Based Clinical Practice GuidelinesChest2004126SupplS1434
   Google Scholar
• GalièNTorbickiABarstRGuidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of CardiologyEur Heart J2004252243227815589643
   PubMed Web of Science ®Google Scholar
• MiyamotoSNagayaNSatohTClinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testingAm J Resp Crit Care Med200016148749210673190
   PubMed Web of Science ®Google Scholar
• SanchezOSitbonOJaïsXSimonneauGHumbertGImmunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertensionChest200613018218916840400
   PubMed Web of Science ®Google Scholar
• JaisXLaunayDYaiciAImmunosuppressive therapy in lupus- and mixed connective tissue disease–associated pulmonary arterial hypertension a retrospective analysis of twenty-three casesArthritis Rheum20085852153118240255
   PubMed Web of Science ®Google Scholar
• HoeperMMMarkevychISpiekerkoetterEWelteTNiedermeyerJGoal-oriented treatment and combination therapy for pulmonary arterial hypertensionEur Respir J20052685886316264047
   PubMed Web of Science ®Google Scholar
• GibbsSCorrisPfor National pulmonary hypertension centres of the UK and IrelandConsensus statement on the management of pulmonary hypertension in clinical practice in the UK and IrelandHeart200894Suppl Ii1i4118276826
   PubMedGoogle Scholar
• SitbonOGressinVSpeichRBosentan for the treatment of human immunodeficiency virus–associated pulmonary arterial hypertensionAm J Respir Crit Care Med20041701212121715317666
   PubMed Web of Science ®Google Scholar
• BarstRJIvyDDingemanseJPharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertensionClin Pharmacol Ther20037337238212709727
   PubMed Web of Science ®Google Scholar
• GalièNBeghettiMGatzoulisMABosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled studyCirculation2006114485416801459
   PubMed Web of Science ®Google Scholar
• JaïsXD’ArminiAMJansaPBosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronic Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trialJ Am Coll Cardiol2008522127213419095129
   PubMed Web of Science ®Google Scholar
• McLaughlinVVArcherSLBadeschDBACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart AssociationJ Am Coll Cardiol2009531573161919389575
   PubMed Web of Science ®Google Scholar
• KenyonKWNappiJMBosentan for the treatment of pulmonary arterial hypertensionAnn Pharmacother2003371055106212841819
   PubMed Web of Science ®Google Scholar
• MotteSMcEnteeKNaeijeREndothelin receptor antagonistsPharmacol Ther200611038641416219361
   PubMed Web of Science ®Google Scholar
• OpitzCFEwertRKirchWPittrowDInhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matterEur Heart J2008291936194818562303
   PubMed Web of Science ®Google Scholar
• DingemanseJvan GiersbergenPLClinical pharmacology of bosentan, a dual endothelin receptor antagonistClin Pharmacokinet2004431089111515568889
   PubMed Web of Science ®Google Scholar
• van GiersbergenPLHalabiADingemanseJPharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiolInt J Clin Pharmacol Ther20064411311816550733
   PubMed Web of Science ®Google Scholar
• TreiberASchneiterRHäuslerSStiegerBBosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafilDrug Metab Dispos2007351400140717496208
   PubMed Web of Science ®Google Scholar
• van GiersbergenPLTreiberASchneiterRDietrichHDingemanseJInhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjectsClin Pharmacol Ther20078141441917251982
   PubMed Web of Science ®Google Scholar
• McRaeMPLoweCMTianXRitonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytesJ Pharmacol Exp Ther20063181068107516720753
   PubMed Web of Science ®Google Scholar
• BurgessGHoogkamerHCollingsLDingemanseJMutual pharmacokinetic interactions between steady-state bosentan and sildenafilEur J Clin Pharmacol200864435018040672
   PubMed Web of Science ®Google Scholar
• WrishkoREDingemanseJYuADarsteinCPhillipsDLMitchellMIPharmacokinetic interaction between tadalafil and bosentan in healthy male subjectsJ Clin Pharmacol20084861061818305126
   PubMed Web of Science ®Google Scholar
• WilliamsonDJWallmanLLJonesRHemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertensionCirculation200010241141810908213
   PubMed Web of Science ®Google Scholar
• ChannickRNSimmoneauGSitbonOEffects of the dual endothelin-receptor antagonist Bosentan in patients with pulmonary hypertension: a randomised placebo-controlled studyLancet20013581119112311597664
   PubMed Web of Science ®Google Scholar
• RubinLJBadeschDBBarstRJBosentan therapy for pulmonary arterial hypertensionNew Eng J Med200234689690311907289
   PubMed Web of Science ®Google Scholar
• HumbertMBarstRJRobbinsIMCombination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2Eur Respir J20042435335915358690
   PubMed Web of Science ®Google Scholar
• WilkinsMRPaulGAStrangeJWSildenafil versus Endothelin receptor Antagonist for Pulmonary Hypertension (SERAPH) studyAm J Respir Crit Care Med20051711292129715750042
   PubMed Web of Science ®Google Scholar
• BarstRJLanglebenDBadeschDfor STRIDE-2 Study GroupTreatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentanJ Am Coll Cardiol2006472049205616697324
   PubMed Web of Science ®Google Scholar
• MathaiSCGirgisREFisherMRAddition of sildenafil to bosentan monotherapy in pulmonary arterial hypertensionEur Respir J20072946947517079256
   PubMed Web of Science ®Google Scholar
• DentonCPPopeJEPeterHHLong-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseasesAnn Rheum Dis2008671222122818055477
   PubMed Web of Science ®Google Scholar
• AkagiSMatsubaraHMiyajiKAdditional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenolCirc J2008721142114618577825
   PubMed Web of Science ®Google Scholar
• GalièNRubinLJHoeperMMTreatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trialLancet20083712093210018572079
   PubMed Web of Science ®Google Scholar
• SitbonOBadeschDChannickRNEffects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension. A 1-year follow-up studyChest200312424725412853530
   PubMed Web of Science ®Google Scholar
• McLaughlinVVSurvival in patients with pulmonary arterial hypertension treated with first-line bosentanEur J Clin Invest200636Suppl 3101516919005
   PubMed Web of Science ®Google Scholar
• DentonCPHumbertMRubinLBlackCMBosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensionsAnn Rheum Dis2006651336134016793845
   PubMed Web of Science ®Google Scholar
• GatzoulisMABeghettiMGalièNLonger-term bosentan therapy improves functional capacity in Eisenmenger syndrome: Results of the BREATHE-5 open-label extension studyInt J Cardiol2008127273217658633
   PubMed Web of Science ®Google Scholar
• FrostAELanglebenDOudizRThe 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effectVascul Pharmacol200543363915890561
   PubMed Web of Science ®Google Scholar
• GalièNGhofraniHATorbickiAfor the Sildena fil Use in Pulmonary Arterial Hypertension (SUPER) Study GroupSildenafil citrate therapy for pulmonary arterial hypertensionN Engl J Med20053532148215716291984
   PubMed Web of Science ®Google Scholar
• GalièNBadeschDOudizRAmbrisentan therapy for pulmonary arterial hypertensionJ Am Coll Cardiol20054652953516053970
   PubMed Web of Science ®Google Scholar
• GalièNOlschewskiHOudizRJAmbrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2Circulation20081173010301918506008
   PubMed Web of Science ®Google Scholar
• SimonneauGBarstRJGalièNContinuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trialAm J Respir Crit Care Med200216580080411897647
   PubMed Web of Science ®Google Scholar
• GalièNHumbertMVachiéryJLfor Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study GroupEffects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trialJ Am Coll Cardiol2002391496150211985913
   PubMed Web of Science ®Google Scholar
• BarstRJMcGoonMMcLaughlinVfor Beraprost Study GroupBeraprost therapy for pulmonary arterial hypertensionJ Am Coll Cardiol2003412119212512821234
   PubMed Web of Science ®Google Scholar
• BarstRJLanglebenDFrostAfor STRIDE-1 Study GroupSitaxsentan therapy for pulmonary arterial hypertensionAm J Respir Crit Care Med200416944144714630619
   PubMed Web of Science ®Google Scholar
• SastryBKSNarasimhanCReddyNKRajuBSClinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double- blind, crossover studyJ Am Coll Cardiol2004431149115315063421
   PubMed Web of Science ®Google Scholar
• SimonneauGRubinLGalièNfor the Pulmonary Arterial Hypertension combination Study of Epoprostenol Sildenafil (PACES) Study GroupAddition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertensionAnn Intern Med200814952153018936500
   PubMed Web of Science ®Google Scholar
• TorresFLong-term ambrisentan therapy in patients with pulmonary arterial hypertension: an analysis by WHO Functional Class [abstract]Am J Respir Crit Care Med2009179A3370
   Web of Science ®Google Scholar
• HoeperMMFaulenbachCGolponHWinklerJWelteTNiedermeyerJCombination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertensionEur Respir J2004241007101015572546
   PubMed Web of Science ®Google Scholar
• SitbonOMcLaughlinVVBadeschDBSurvival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenolThorax2005601025103016055621
   PubMed Web of Science ®Google Scholar
• BenzaRLFrostAGirgisRLanglebenDLawrenceECNaeijeRChronic treatment of pulmonary arterial hypertension (PAH) with sitax-entan and bosentan [abstract]Proc Am Thorac Soc20063A729
   Google Scholar
• HighlandKBStrangeCGirgisREBlackCComparison of sitaxentan and bosentan in pulmonary arterial hypertension associated with connective tissue disease [abstract]Ann Rheum Dis200665Suppl 2393
   Google Scholar
• No author listedTracleer (bosentan tablets) 62.5 and 125 mg film-coated tablets http://www.tracleer.com/pdf/01 001 01 09 0309_Tra_PromoPI_SinglePages_TR4385_030409_FINAL.pdfAccessed April 2009
   Google Scholar
• SegalSTravcleer_dhcp_final.pdf [Letter dated 2006 March 1]United States Food and Drug Administration [safety information pages]Silver Spring [updated 2009 June 19; cited 2009 June 19]. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150762.htmAccessed April 2009
   Google Scholar
• DwyerNJonesGKilpatrickDSevere hepatotoxicity in a patient on bosentan upon addition of methotrexate: reversible with resumption of methotrexate without bosentanJ Clin Rheumatol200915888919265355
   PubMed Web of Science ®Google Scholar
• GalièNManesANegroLPalazziniMBacchi-ReggianiMLBranziAA meta-analysis of randomized controlled trials in pulmonary arterial hypertensionEur Heart J20093039440319155250
   PubMed Web of Science ®Google Scholar